Blockchain Registration Transaction Record

Optimi Health Ships First Psilocybin to UK for Phase 2 Trial

Optimi Health completes first export of naturally derived psilocybin to the UK for a Phase 2 clinical trial, supporting mental health therapies for treatment-resistant depression.

This export marks a critical milestone in the global expansion of psychedelic-assisted therapy. By supplying GMP-grade psilocybin for a UK clinical trial, Optimi is helping to advance research into treatment-resistant depression, a condition affecting millions worldwide. For investors, it signals growing regulatory acceptance and commercial viability of psychedelic medicines. For patients, it brings hope for new, effective treatments that could transform mental healthcare.